Laronde
Cambridge
About Laronde
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $490.0M
- Funding stage: M&A
- Last round: Series B (Aug 2021)
- Website: laronde.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/laronde-71511 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.